The pharmacologic basis of high dose chemotherapy with haematopoietic stem cell support for solid tumours

The theoretical basis of high dose chemotherapy with haematopoietic stem cell support (HDT) for solid tumours is the presumption of a linear, steep dose-response relationship for chemotherapy conditioning agents. We review preclinical pharmacologic studies evaluating steep dose-response relationship...

Descripción completa

Detalles Bibliográficos
Autores principales: Porrata, L F, Adjei, A A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364096/
https://www.ncbi.nlm.nih.gov/pubmed/11506483
http://dx.doi.org/10.1054/bjoc.2001.1970
_version_ 1782153868617973760
author Porrata, L F
Adjei, A A
author_facet Porrata, L F
Adjei, A A
author_sort Porrata, L F
collection PubMed
description The theoretical basis of high dose chemotherapy with haematopoietic stem cell support (HDT) for solid tumours is the presumption of a linear, steep dose-response relationship for chemotherapy conditioning agents. We review preclinical pharmacologic studies evaluating steep dose-response relationships for different chemotherapeutic agents, identified through a MED-LINE and CANCER-LIT search of the English medical literature from January 1966 to December 1999. Only BCNU, melphalan, nitrogen mustard, and the combination of thiotepa and cyclophosphamide demonstrated steep dose-response relationships over a wide dose-range. The pharmacologic evidence for the use of other antineoplastic agents for HDT in solid tumours is non-existent. More preclinical studies are needed for a rational development of this therapeutic approach for solid tumours. © 2001 Cancer Research Campaign http://www.bjcancer.com
format Text
id pubmed-2364096
institution National Center for Biotechnology Information
language English
publishDate 2001
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23640962009-09-10 The pharmacologic basis of high dose chemotherapy with haematopoietic stem cell support for solid tumours Porrata, L F Adjei, A A Br J Cancer Review The theoretical basis of high dose chemotherapy with haematopoietic stem cell support (HDT) for solid tumours is the presumption of a linear, steep dose-response relationship for chemotherapy conditioning agents. We review preclinical pharmacologic studies evaluating steep dose-response relationships for different chemotherapeutic agents, identified through a MED-LINE and CANCER-LIT search of the English medical literature from January 1966 to December 1999. Only BCNU, melphalan, nitrogen mustard, and the combination of thiotepa and cyclophosphamide demonstrated steep dose-response relationships over a wide dose-range. The pharmacologic evidence for the use of other antineoplastic agents for HDT in solid tumours is non-existent. More preclinical studies are needed for a rational development of this therapeutic approach for solid tumours. © 2001 Cancer Research Campaign http://www.bjcancer.com Nature Publishing Group 2001-08 /pmc/articles/PMC2364096/ /pubmed/11506483 http://dx.doi.org/10.1054/bjoc.2001.1970 Text en Copyright © 2001 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Review
Porrata, L F
Adjei, A A
The pharmacologic basis of high dose chemotherapy with haematopoietic stem cell support for solid tumours
title The pharmacologic basis of high dose chemotherapy with haematopoietic stem cell support for solid tumours
title_full The pharmacologic basis of high dose chemotherapy with haematopoietic stem cell support for solid tumours
title_fullStr The pharmacologic basis of high dose chemotherapy with haematopoietic stem cell support for solid tumours
title_full_unstemmed The pharmacologic basis of high dose chemotherapy with haematopoietic stem cell support for solid tumours
title_short The pharmacologic basis of high dose chemotherapy with haematopoietic stem cell support for solid tumours
title_sort pharmacologic basis of high dose chemotherapy with haematopoietic stem cell support for solid tumours
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364096/
https://www.ncbi.nlm.nih.gov/pubmed/11506483
http://dx.doi.org/10.1054/bjoc.2001.1970
work_keys_str_mv AT porratalf thepharmacologicbasisofhighdosechemotherapywithhaematopoieticstemcellsupportforsolidtumours
AT adjeiaa thepharmacologicbasisofhighdosechemotherapywithhaematopoieticstemcellsupportforsolidtumours
AT porratalf pharmacologicbasisofhighdosechemotherapywithhaematopoieticstemcellsupportforsolidtumours
AT adjeiaa pharmacologicbasisofhighdosechemotherapywithhaematopoieticstemcellsupportforsolidtumours

Ejemplares similares